Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response

Efficacy of infliximab in Crohn's disease (CD) showed by randomized controlled trials must be confirmed in clinical practice. We aimed to evaluate efficacy and safety of infliximab in CD patients of the Madrid area, looking for clinical predictors of response. Multicenter retrospective survey o...

Full description

Saved in:

Bibliographic Details
Published in:	Gastroenterología y hepatología Vol. 31; no. 7; p. 421
Main Authors:	González-Lama, Yago, López-San Román, Antonio, Marín-Jiménez, Ignacio, Casis, Begoña, Vera, Isabel, Bermejo, Fernando, Pérez-Calle, José Lázaro, Taxonera, Carlos, Martínez-Silva, Francisca, Menchén, Luis, Martínez-Montiel, Pilar, Calvo, Marta, Carneros, José Antonio, López, Pilar, Mendoza, Juan Luis, Milicua, José María, Huerta, Alaín, Sánchez, Fernando, Abreu, Luis, López-Palacios, Natalia, Maté, José, Gisbert, Javier P
Format:	Journal Article
Language:	English
Published:	Spain 01-08-2008
Subjects:	Adolescent Adult Aged Aged, 80 and over Anti-Inflammatory Agents - adverse effects Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Crohn Disease - drug therapy Female Humans Infliximab Male Middle Aged Retrospective Studies Time Factors Young Adult
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!